What are the approved indications for stem cell therapy in Japan according to medical insights?
Approved Indications for Stem Cell Therapy in Japan According to Medical Insights
Japan has approved stem cell therapy for a narrow set of conditions, primarily through the Act on Securing Safety of Regenerative Medicine (enacted in 2014) and the Pharmaceutical and Medical Device Act. As of 2025, the only widely accepted, government-approved indications include graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation, acute myocardial infarction (heart attack) using autologous bone marrow-derived cells, and spinal cord injury under specific clinical trial protocols. For chronic conditions like osteoarthritis or Parkinson’s disease, Japan has not granted full approval—only conditional, risk-based licenses for research or private clinics operating under the “Class II” or “Class III” regenerative medicine plans. You can find more details on Japan Medical insights on stem cell therapy indications in Japan.
Let’s break this down with hard numbers and real-world context. The Japanese regulatory framework is unique because it separates “approved” from “licensed” therapies. Under the Pharmaceutical and Medical Device Act (PMD Act), only two stem cell products have received full marketing approval: Temcell (for GVHD) and HeartSheet (for heart failure). Temcell, a mesenchymal stem cell product from Japan’s JCR Pharmaceuticals, was approved in 2015 after a phase II trial showing a 67% response rate in 30 patients with steroid-resistant GVHD. HeartSheet, a myoblast sheet from Terumo Corporation, got approval in 2016 based on a study of 27 patients with severe heart failure, showing a 30% reduction in left ventricular end-systolic volume. These are the only two products with “full” regulatory approval—meaning they can be marketed and reimbursed by Japan’s public health insurance.
Now, the Act on Securing Safety of Regenerative Medicine (ASRM) created a different pathway. It allows clinics to offer stem cell therapies for “unapproved” indications if they submit a plan to the Ministry of Health, Labour and Welfare (MHLW) and get approval from a certified committee. Under this law, there are three risk classes: Class I (high risk, e.g., embryonic stem cells), Class II (medium risk, e.g., somatic stem cells), and Class III (low risk, e.g., minimally manipulated cells). As of 2023, the MHLW reported over 2,500 submitted plans for Class II and III therapies, covering conditions like knee osteoarthritis, liver cirrhosis, type 1 diabetes, and spinal cord injury. But here’s the catch: these are not “approved” in the traditional sense—they are “licensed” for clinical use under strict monitoring, meaning the government tracks outcomes but doesn’t guarantee efficacy. A 2022 study in Regenerative Medicine journal found that only 12% of these plans had published peer-reviewed results after 5 years, highlighting a gap between regulatory permission and proven effectiveness.
Let’s drill into specific indications with data. For spinal cord injury, Japan’s Osaka University and Keio University have conducted trials using induced pluripotent stem cells (iPSCs). In 2019, a team led by Dr. Hideyuki Okano transplanted iPSC-derived neural stem cells into 4 patients with complete spinal cord injury. After 1 year, 2 patients showed improved motor function (e.g., moving legs without assistance). However, the MHLW has not approved this as a standard therapy—it remains under a “Class I” clinical research protocol. For acute myocardial infarction, the Juntendo University trial in 2017 used autologous bone marrow-derived mesenchymal stem cells in 30 patients, showing a 15% increase in ejection fraction after 6 months. Yet, the Japanese Circulation Society guidelines still list stem cell therapy as “experimental” for heart disease, not standard care.
What about osteoarthritis? This is a hot topic. In Japan, over 1,000 private clinics offer stem cell injections for knee pain, often using adipose-derived or bone marrow-derived cells. But the Japan Orthopaedic Association has stated that “there is insufficient evidence to recommend routine use.” A 2021 meta-analysis of 12 Japanese studies (total 450 patients) found a 40% reduction in pain scores at 6 months, but the placebo effect was also around 30%. The MHLW has not approved any stem cell product for osteoarthritis—only “Class II” licenses for clinics to offer it as a “medical procedure” without insurance coverage. Patients pay out-of-pocket, typically ¥1.5 million to ¥3 million (about $10,000 to $20,000) per session.
Let’s look at a table to summarize the approved vs. licensed indications:
| Condition | Regulatory Status | Product/Protocol | Evidence Level | Cost to Patient |
|---|---|---|---|---|
| Graft-vs-Host Disease | Full approval (PMD Act) | Temcell (mesenchymal stem cells) | Phase II trial (67% response) | Covered by insurance |
| Heart Failure | Full approval (PMD Act) | HeartSheet (myoblast sheet) | Phase II trial (30% volume reduction) | Covered by insurance |
| Spinal Cord Injury | Class I clinical research | iPSC-derived neural stem cells | Phase I/II (2/4 patients improved) | Research-funded |
| Acute Myocardial Infarction | Class II licensed (not approved) | Autologous bone marrow cells | Single-center trial (15% EF increase) | Out-of-pocket (¥2-3 million) |
| Osteoarthritis | Class II/III licensed | Adipose-derived stem cells | Meta-analysis (40% pain reduction) | Out-of-pocket (¥1.5-3 million) |
| Type 1 Diabetes | Class II clinical research | Mesenchymal stem cells | Small trials (C-peptide increase) | Research-funded |
This table shows the stark reality: only two indications have full approval, and they are niche. The rest are either research protocols or licensed procedures with limited evidence. The Japanese Society for Regenerative Medicine reported in 2023 that over 80% of stem cell treatments in Japan are for “anti-aging” or “cosmetic” purposes, which fall outside the ASRM’s medical indications. These are unregulated, and the MHLW has issued warnings about clinics making false claims.
Let’s talk about safety data. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) tracks adverse events. From 2015 to 2023, there were 47 reported serious adverse events related to stem cell therapies, including infections, tumor formation, and immune reactions. For Temcell, the most common side effect was fever (12% of patients), and no tumors were reported in the 5-year follow-up. For HeartSheet, arrhythmias occurred in 15% of patients. For licensed Class II therapies, the PMDA reported 3 cases of ectopic tissue formation (e.g., bone growing in the knee) after adipose-derived stem cell injections. The overall risk is low, but it’s not zero.
Now, why does Japan have this two-tier system? The ASRM was designed to accelerate innovation while maintaining safety. It allows clinics to offer therapies without full clinical trials, as long as they follow safety protocols. This has led to a boom in “stem cell tourism” within Japan, with an estimated 10,000 patients per year receiving unapproved treatments. But the Japan Medical Association has criticized this, saying it creates a “wild west” environment. A 2024 survey by Nikkei Medical found that 60% of Japanese doctors believe stem cell therapy is overhyped, and only 15% would recommend it to a family member.
For neurological conditions, Japan has approved iPSC-based therapies for Parkinson’s disease under a Class I research protocol. In 2022, Kyoto University transplanted iPSC-derived dopamine neurons into 7 patients, and after 2 years, 3 showed a 20% improvement in motor scores. But this is not approved for routine use—the MHLW requires a phase III trial with at least 100 patients before considering full approval. Similarly, for age-related macular degeneration, Japan was the first country to use iPSC-derived retinal pigment epithelium cells in humans (2014), but only 2 patients have been treated, and the program is on hold due to regulatory hurdles.
What about hematological cancers? Hematopoietic stem cell transplantation (HSCT) is fully approved for leukemia and lymphoma, but that’s a different category—it’s bone marrow or blood stem cells, not the “regenerative” stem cells people think of. Japan performs about 5,000 HSCTs per year, with a 5-year survival rate of 60% for acute leukemia. This is standard care, not experimental.
Let’s get into cost and insurance. Only Temcell and HeartSheet are covered by Japan’s National Health Insurance (NHI). For Temcell, the cost is about ¥1.2 million ($8,000) per dose, and patients pay 10-30% co-pay depending on age. For HeartSheet, the procedure costs ¥5 million ($33,000), but insurance covers 70%. For licensed Class II therapies, patients pay 100% out-of-pocket, and the average cost per session is ¥2.5 million ($16,500). A 2023 study in Health Policy found that only 5% of Japanese patients could afford such treatments without financial hardship.
Now, future directions. Japan’s Ministry of Economy, Trade and Industry has invested ¥110 billion ($730 million) in regenerative medicine research from 2015 to 2025. The goal is to approve 5 new stem cell products by 2027, including for spinal cord injury and Parkinson’s disease. But the PMDA has tightened requirements after a scandal in 2018 where a clinic in Tokyo used unapproved stem cells for cancer treatment, leading to a patient’s death. Now, all Class I and II plans must be registered in a public database, and clinics must report outcomes every 6 months.
In summary, Japan’s approved indications for stem cell therapy are limited to GVHD and heart failure with full approval, plus a few licensed indications under strict monitoring. The rest is research or unregulated. The system is pragmatic but flawed, balancing innovation with safety. For patients, it’s crucial to check if the therapy is “approved” (PMD Act) or just “licensed” (ASRM), as the latter has no guarantee of efficacy. The Japan Medical insights on stem cell therapy indications in Japan provide a clear roadmap: only two products have passed the highest bar, and the rest are still in the gray zone.